XNPT XenoPort's stock surges after psoriasis treatment meets trial's primary endpoint
16 minutes ago - DJNF
XenoPort Inc.'s stock (XNPT) surged 9.5% in premarket trade Tuesday, after the company announced positive results from a Phase 2 trial of its treatment for psoriasis. The company said its treatment, known as XP23829, met its primary endpoints in the trial for both 800 milligram once daily and 400 milligram twice daily doses. "We believe these clinical data demonstrate for the first time that a [monomethyl fumarate] prodrug other than dimethyl fumarate (DMF) can be effective in reducing lesions in psoriatic patients," said XenoPort Chief Medical Officer Richard Kim. The company said TXP23829 was also safe and generally well tolerated. The stock has gained 5.2% over the past three months through Monday, while the S&P 500 has lost 6.3%.
-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
September 15, 2015 07:51 ET (11:51 GMT)
DUKE BASKETBALL and NOTRE DAME FOOTBALL
